Accessibility tools
East Genomics

Genomic Laboratory Hub

The East Genomic Laboratory Hub (or East GLH) provides and coordinates a wide range of genomic tests for the East Midlands and East of England.

East GLH is one of seven hubs within England which together make up the national genomic laboratory service.

With our lead laboratory at Cambridge University Hospitals NHS Foundation Trust and local laboratories at Nottingham University Hospitals NHS Trust and University Hospitals of Leicester NHS Trust we are well placed to provide high quality genetic and genomic testing for all the 29 NHS Trusts we serve.

We aim to provide equal access to testing across a population of over 8.3 million people. We provide and coordinate tests, within the agreed turn around times, according to the National Test Directory for:

  • rare and inherited disease
  • cancer
  • haematological malignancy

Our laboratories only accept samples from clinicians once a clinical referral has been made.

The NHS Trusts that we serve are:

  • Bedfordshire Hospitals NHS Foundation Trust
  • Cambridge University Hospitals NHS Foundation Trust - lead laboratory
  • Cambridgeshire and Peterborough NHS Foundation Trust
  • Cambridgeshire Community Services NHS Trust
  • Derbyshire Community Health Services NHS Foundation Trust
  • Derbyshire Healthcare NHS Foundation Trust
  • East and North Hertfordshire NHS Trust
  • East Suffolk and North Essex NHS Foundation Trust
  • James Paget University Hospitals NHS Foundation Trust
  • Kettering General Hospital NHS Foundation Trust
  • Leicestershire Partnership NHS Trust
  • Lincolnshire Community Health Services NHS Trust
  • Lincolnshire Partnership NHS Foundation Trust
  • Norfolk and Norwich University Hospitals NHS Foundation Trust
  • Norfolk and Suffolk NHS Foundation Trust
  • Norfolk Community Health and Care NHS Trust
  • Essex Partnership University NHS Foundation Trust
  • North West Anglia NHS Foundation Trust
  • Northampton General Hospital NHS Trust
  • Northamptonshire Healthcare NHS Foundation Trust
  • Nottingham University Hospitals NHS Trust - local laboratory
  • Nottinghamshire Healthcare NHS Foundation Trust
  • Royal Papworth Hospital NHS Foundation Trust
  • Sherwood Forest Hospitals NHS Foundation Trust
  • The Queen Elizabeth Hospital King’s Lynn NHS Foundation Trust
  • United Lincolnshire Hospitals NHS Trust
  • University Hospitals of Derby and Burton NHS Foundation Trust
  • University Hospitals of Leicester NHS Trust - local laboratory
  • West Suffolk NHS Foundation Trust

The quality of our service

The constituent laboratories of the East GLH are each accredited for the provision of diagnostic services.

The scope of services offered for laboratory testing is accredited by the United Kingdom Accreditation Service (UKAS) to ISO 15189:2012 standards (Medical Laboratory 8290).

Accreditation, for which we are reviewed annually, provides assurance that:

  • we perform to the required standard
  • clinical and administrative practices are delivered competently
  • the resources, facilities and workforce are appropriate
  • service delivery is patient-focused
  • the performance of the service can be sustained

The Cambridge Genomic Laboratory, East GLH, is a UKAS accredited medical laboratory No.8840 (and 10003). Details of the Scope of our Accreditation and the testing performed is available via the UKAS website.

Note on scheme providers used for EQA: From 1st January, 2018 Cytogenomics External Quality Assessment Service (CEQAS) and UK National External Quality Assessment Service (UK NEQAS) Molecular Genetics merged to become Genomics Quality Assessment (GenQA). GenQA is part of the UK NEQAS Consortium.

EQA schemes and performance

The department is registered with the EQA schemes listed below and participates in all rounds available covering our scope of service. This may include:

UK NEQAS: United Kingdom national external quality assessment schemes
  • Acute Myeloid Leukaemia Gene Panels (Pilot) Leucocyte Immunophenotyping
  • BCR-ABL1 and AML Translocations Identification: Leucocyte Immunophenotyping
  • BCR-ABL1 Kinase Domain Variant (Mutation) Status: Leucocyte Immunophenotyping
  • Major BCR-ABL1 Quantification: Leucocyte Immunophenotyping
  • Chronic Lymphocytic Leukaemia Gene Panels
  • FLT3 Mutation Status: Leucocyte Immunophenotyping
  • JAK2 p.Val617Phe (V617F) Mutation Status: Leucocyte Immunophenotyping
  • KIT p.Asp816Val (D816V) Mutation Status for Mast Cell Disease
  • Lymphoplasmacytic Lymphoma / Waldenstrom Macroglobulinaemia
  • Myeloproliferative Neoplasms Gene Panels
  • NPM1 Mutation Status (for HRM assay - diagnosis)
  • Paediatric Acute Leukaemia Translocations: Leucocyte Immunophenotyping
  • Post-SCT Chimerism Monitoring: Leucocyte Immunophenotyping
  • Full Blood Count (for white cell counts)
Genomics Quality Assessment (GenQA) 2021-2022 schemes
  • Acquired array (CLL and MDS) - Array
  • Chronic Lymphocytic Leukaemia (CLL) (previously Mature B & T FISH & Mature B & T G-band)
  • Colorectal cancer option 3 extended MMR
  • Lung cancer - option 3 comprehensive
  • Lung cancer - Circulating free (CF) DNA in lung cancer
  • Melanoma
  • Central Nervous System (CNS) Tumours
  • Chronic Lymphocytic Leukaemia (CLL) IGHV mutation status
  • DNA extraction from venous blood
  • DNA extraction from FFPE tissue
  • DNA extraction from Fresh/Frozen tissue
  • DNA extraction from saliva
  • DNA Quantification
  • Gastrointestinal stromal tumours (GIST)
  • Lymphoma (previously mature B&T FISH and mature B&T G-band)
  • Microsatellite instability testing (MSI)
  • Neuroblastoma
  • Next generation sequencing (NGS) somatic
  • NGS germline
  • Sarcoma
  • Molecular Tissue Identification
  • Pan cancer NTRK testing
  • Pathogenicity of somatic sequence variant (Classification only)
  • Tissue-i
  • Myeloid Disorders
  • Myeloma
  • Haematological technical FISH
  • Acute lymphoblastic leukaemia (ALL)
  • Maternal cell contamination (MCC) and fetal sexing
  • Pregnancy loss (molecular methods)
  • Prenatal constitutional cop number variation (CNV) detection
  • Prenatal karyotyping (previously AF and CVS)
  • Rapid prenatal testing for common aneuploidies (previously RA-FISH and MRA)
  • Recurrent mis-carriage karyotyping (previously blood postnatal)
  • Sex chromosome disorders karyotyping (previously blood postnatal)
  • Molecular testing for cystic fibrosis (CF)
  • Induced pluripotent stems (IPS) cells
  • Postnatal constitutional CNV detection
  • Disorders of sexual development (DSD)
  • Infertility
  • Severe developmental delay
  • Ataxia, including Hereditary Spastic Paraplegia (HSP)
  • Charcot Marie Tooth disease and related sensory and motor neuropathies
  • Cystic fibrosis and CFTR-related disorders
  • Epilepsy disorders
  • Familial colorectal cancer and polyposis
  • Familial endocrine tumour predisposition disorders
  • Familial hypercholesterolaemia
  • Fragile X syndrome and FMR1 related disorders
  • Hereditary breast and ovarian cancer disorders
  • Huntington disease
  • Hypotonic infant
  • Imprinting disorders
  • Linkage analysis
  • Muscular dystrophies
  • Neurodegenerative disorders
  • Skeletal dysplasias, including FGFR2/FGFR3 related disorders
  • X-inactivation
  • Aminoglycoside induced deafness
  • Prediction of 5-fluorouracil toxicity
  • Acquired array (CLL and MDS)
  • Ovarian cancer - BRCA testing in ovarian cancer (germline)
  • Ovarian cancer - BRCA testing in ovarian cancer (somatic)
  • Renal tumours
  • Thyroid cancer
  • Exome sequencing data interpretation
  • ISCN accuracy
  • Pathogenicity of germline sequence variants (classification and interpretation)
  • Pathogenicity of germline postnatal copy number variants (CNV)
  • BRCA variant classification
  • Single nucleotide variant (SNV) classification (trial)
  • Copy nucleotide variant (CNV) classification (trial)
European Molecular Genetics Quality Network (EMQN)
  • Hereditary Haemochromatosis
  • Stickler syndrome
EuroClonality network
  • IG/TR Clonality Testing in Suspected Lymphoproliferations/Lymphoma